WELCOME TO ONCOSCIENCE

About Us

At Oncoscience GmbH, a proud member of Innokeys Pte Ltd, we are committed to advancing cancer care through innovative research and the development of therapies for rare cancers and orphan diseases. Our efforts focus on addressing unmet medical needs and supporting the development of personalized treatment options, with the goal of contributing to better patient care. By combining advanced diagnostic tools with targeted therapeutic approaches, we strive to improve the treatment landscape for patients with rare and complex conditions.

Oncology

Oncology deals with the diagnosis and treatment of cancer, a diverse group of diseases that often require specialised therapeutic approaches. Rare diseases affect only a small proportion of the population and are often associated with limited treatment options and research challenges. Orphan drugs are therapies that are specifically developed to meet the unique needs of patients with rare diseases and rare cancers.

Oncoscience GmbH focuses on the research and development of therapies for rare cancers and rare diseases. With a precision medicine approach, we aim to promote innovative treatment concepts in order to close gaps in care in these areas.

Countries approved
0
Clinical Trials
0
Patients Treated
0
Publications
0

About Nimotuzumab

Nimotuzumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), which is frequently overexpressed in certain cancers such as head and neck cancer, glioma and nasopharyngeal carcinoma. By specifically binding to the EGFR receptor, the signalling involved in the regulation of cell growth and division is influenced. Nimotuzumab is included in certain approved therapy concepts and is being researched for various tumour entities.

Research

At Oncoscience GmbH, we focus on research and development in the field of rare cancers. Our aim is to gain new insights into oncology through scientific studies and collaboration with international experts. An important focus of our work is scientific research into nimotuzumab, particularly in the context of clinical studies to investigate its mechanism of action and its potential therapeutic applications.

Find out more about our current research projects, scientific publications and clinical trials aimed at developing new treatment options for patients with rare and complex cancers.

FAQ

Visit our FAQ page for clear answers to the most common inquiries. Our FAQ section provides valuable insights and guidance to help you navigate your options.